



September 26, 2012

Notice of Revision of Financial Forecast

In light of the recent trend in our business performance, Hisamitsu Pharmaceutical Co., Inc., (“Hisamitsu”) hereby revises, as follows, the financial forecast for the second quarter (cumulative) of the fiscal year ending February 28, 2013, which had been released on April 10, 2012.

1. Revision of Financial Forecast for Second Quarter (Cumulative)

Revised Consolidated Financial Forecast for Second Quarter (Cumulative) of Fiscal Year Ending February 28, 2013 (March 1, 2012, through August 31, 2012)

(Amounts in millions of yen, except amounts per share in yen)

| | Net Sales | Operating Income | Ordinary Income | Quarterly Net Income | Quarterly Net Income per Share |
|---|-----------|------------------|-----------------|----------------------|--------------------------------|
| Previous Forecast (A) | 71,100 | 10,200 | 13,400 | 7,900 | 92.22 ^{yen} |
| Revised Forecast (B) | 71,900 | 13,200 | 16,400 | 9,300 | 108.56 ^{yen} |
| Variance in Amount (B-A) | 800 | 3,000 | 3,000 | 1,400 | |
| Variance in Percentage (%) | + 1.1% | + 29.4% | + 22.4% | + 17.7% | |
| (Ref.) Second Quarter Results of Prior Fiscal Year (Second Quarter of Fiscal Year Ended February 29, 2012) | 69,160 | 13,214 | 15,908 | 7,087 | 82.63 ^{yen} |

2. Reasons for the Revision

The consolidated operating income, ordinary income, and quarterly net income for the second quarter (cumulative) of the fiscal year ending February 28, 2013, are projected to be higher than in the last forecasts primarily due to lower selling and general administration expenses as a result of the deferral of research and development (R&D) and selling expenses by Hisamitsu and Noven Pharmaceuticals, Inc., to the third quarter onwards.

3. Full Year Financial Forecast for Fiscal Year Ending February 28, 2013

At this juncture, there is no change in the consolidated and nonconsolidated full-year financial forecasts for the fiscal year ending February 28, 2013. Depending on progress in the implementation of R&D themes and measures to promote the sales of our major products, if it becomes necessary for us to revise the full-year financial forecasts for the fiscal year ending February 28, 2013, we will promptly disclose the revisions.

4. Dividends

At this juncture, there is no change in our plan for the payment of interim and year-end dividends.

*The financial forecasts described above are prepared on the basis of information available as of the date of this announcement. Actual financial results may differ from those included in these financial forecasts due to a variety of factors going forward.